Figure 1From: An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT] Study design. Bev = bevacizumab. PD = progressive disease.Back to article page